Everything you need to know about Anlon Healthcare IPO

About

Anlon Healthcare, founded in 2013, is a pharmaceutical company based in Rajkot, Gujarat. The company began its manufacturing operations in 2017 and is engaged in the production of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and nutraceutical compounds. With a focus on quality and compliance, the company operates a single manufacturing facility that is ISO 9001:2015, GMP, and WHO-GMP certified. Anlon Healthcare serves pharmaceutical companies across India and exports to select international markets.

IPO schedule

Issue open date 2025-08-26
Issue close date 2025-08-29
UPI mandate deadline 2025-08-29 (5 PM)
Allotment finalization 2025-09-01
Refund initiation 2025-09-02
Share credit 2025-09-02
Listing date 2025-09-03
Mandate end date 2025-09-15
Lock-in end date for anchor investors (50%) 2025-10-01
Lock-in end date for anchor investors (remaining) 2025-11-30

Issue size

Funds Raised in the IPO Amount
Overall ₹121.03 crores
Fresh Issue ₹121.03 crores

Financials

Financial Year Ended March 2022 March 2023 March 2024 January 2025
Total Assets 84.97 111.54 128.00 160.95
Revenue 57.53 113.12 66.69 77.37
Profit After Tax 0.10 5.82 9.65 11.96

Utilisation of proceeds

Purpose INR crores (%)
Capital expenditure for expansion 30.71 (25.37%)
Repayment/pre-payment, in full or in part, of outstanding borrowings 5.00 (4%)
Working capital requirements 43.15 (35.65%)
General corporate purposes and miscellaneous 42.17 (35%)

Strengths

  • Diverse product portfolio with scalable business operations.
  • Experienced promoters and competent management team.
  • High entry barriers due to strict approval standards.
  • In-house testing ensures consistent quality and compliance.
  • Emphasis on Quality, Environment, Health, and Safety (QEHS).

Risks

  • High dependency on single manufacturing unit in Rajkot, Gujarat.
  • Revenue concentration from top few pharmaceutical industry customers.
  • Limited experience in complex pharma intermediates manufacturing.
  • Heavy reliance on select suppliers from western India.
  • Delay in regulatory approvals can halt operations and revenue.
1 Like